These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 22615190)

  • 1. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA; Krantz MJ; Hiatt WR
    Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease.
    Hiatt WR; Creager MA; Amato A; Brass EP
    J Cardiopulm Rehabil Prev; 2011; 31(2):125-32. PubMed ID: 20861750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
    Brass EP; Cooper LT; Morgan RE; Hiatt WR
    J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
    Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
    Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
    Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP
    Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.
    Strandness DE; Dalman RL; Panian S; Rendell MS; Comp PC; Zhang P; Forbes WP
    Vasc Endovascular Surg; 2002; 36(2):83-91. PubMed ID: 11951094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study.
    Brevetti G; Perna S; Sabbá C; Martone VD; Condorelli M
    J Am Coll Cardiol; 1995 Nov; 26(6):1411-6. PubMed ID: 7594063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease.
    Hiatt WR; Hirsch AT; Creager MA; Rajagopalan S; Mohler ER; Ballantyne CM; Regensteiner JG; Treat-Jacobson D; Dale RA; Rooke T
    Vasc Med; 2010 Jun; 15(3):171-9. PubMed ID: 20212073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats.
    Shiga T; Sahara H; Orito K
    Pharmacology; 2015; 96(5-6):210-6. PubMed ID: 26329263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
    Dawson DL; Cutler BS; Meissner MH; Strandness DE
    Circulation; 1998 Aug; 98(7):678-86. PubMed ID: 9715861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
    J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
    J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
    Regensteiner JG; Ware JE; McCarthy WJ; Zhang P; Forbes WP; Heckman J; Hiatt WR
    J Am Geriatr Soc; 2002 Dec; 50(12):1939-46. PubMed ID: 12473004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of withdrawal of drugs treating intermittent claudication.
    Dawson DL; DeMaioribus CA; Hagino RT; Light JT; Bradley DV; Britt KE; Charles BE
    Am J Surg; 1999 Aug; 178(2):141-6. PubMed ID: 10487267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilostazol: improving walking distance in patients with intermittent claudication.
    Collinson DJ; Donnelly R
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):503-9. PubMed ID: 15225110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carnitine and peripheral arterial disease.
    Hiatt WR
    Ann N Y Acad Sci; 2004 Nov; 1033():92-8. PubMed ID: 15591006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment options in intermittent claudication: the US experience.
    Hiatt WR
    Int J Clin Pract Suppl; 2001 Apr; (119):20-7. PubMed ID: 11355276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
    Samra SS; Bajaj P; Vijayaraghavan KS; Potdar NP; Vyas D; Devani RG; Ballary C; Desai A
    J Indian Med Assoc; 2003 Sep; 101(9):561-2, 564. PubMed ID: 15168999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.